86 related articles for article (PubMed ID: 20629977)
1. Pilot study: rapamycin in advanced hepatocellular carcinoma.
Schöniger-Hekele M; Müller C
Aliment Pharmacol Ther; 2010 Sep; 32(6):763-8. PubMed ID: 20629977
[TBL] [Abstract][Full Text] [Related]
2. Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma.
Subbiah IM; Brown RE; Fallon MB
Hepatology; 2010 Oct; 52(4):1524. PubMed ID: 20680964
[No Abstract] [Full Text] [Related]
3. Impressive regression of primary liver cancer after treatment with sirolimus.
Rizell M; Cahlin C; Friman S; Hafström L; Lönn L; Olausson M; Lindner P
Acta Oncol; 2005; 44(5):496. PubMed ID: 16118084
[No Abstract] [Full Text] [Related]
4. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular cancer, transplantation, and sirolimus.
Wall WJ
Liver Transpl; 2004 Oct; 10(10):1312-4. PubMed ID: 15376337
[No Abstract] [Full Text] [Related]
6. Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma.
Decaens T; Luciani A; Itti E; Hulin A; Roudot-Thoraval F; Laurent A; Zafrani ES; Mallat A; Duvoux C
Dig Liver Dis; 2012 Jul; 44(7):610-6. PubMed ID: 22459565
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.
Shen C; Peng C; Shen B; Zhu Z; Xu N; Li T; Xie J
Oncotarget; 2016 Sep; 7(38):62647-62656. PubMed ID: 27577068
[TBL] [Abstract][Full Text] [Related]
8. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
Toso C; Meeberg GA; Bigam DL; Oberholzer J; Shapiro AM; Gutfreund K; Ma MM; Mason AL; Wong WW; Bain VG; Kneteman NM
Transplantation; 2007 May; 83(9):1162-8. PubMed ID: 17496530
[TBL] [Abstract][Full Text] [Related]
9. The potential role of mTOR inhibitors in non-small cell lung cancer.
Gridelli C; Maione P; Rossi A
Oncologist; 2008 Feb; 13(2):139-47. PubMed ID: 18305058
[TBL] [Abstract][Full Text] [Related]
10. mTOR and P70 S6 kinase expression in primary liver neoplasms.
Sahin F; Kannangai R; Adegbola O; Wang J; Su G; Torbenson M
Clin Cancer Res; 2004 Dec; 10(24):8421-5. PubMed ID: 15623621
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of transarterial chemoembolization with pirarubicin and amiodarone for unresectable hepatocellular carcinoma.
Guiu B; Colin C; Cercueil JP; Loffroy R; Guiu S; Ferrant E; Jouve JL; Bonnetain F; Boulin M; Ghiringhelli F; Minello A; Hillon P; Bedenne L; Krause D; Chauffert B
Am J Clin Oncol; 2009 Jun; 32(3):238-44. PubMed ID: 19349854
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin as a novel target in the treatment of hepatocellular carcinoma.
Guo Y; Liang X; Lu M; Weng T; Liu Y; Ye X
Hepatogastroenterology; 2010; 57(101):913-8. PubMed ID: 21033251
[TBL] [Abstract][Full Text] [Related]
14. Liver resection associated with mini porto-caval shunt as salvage treatment in patients with progression of hepatocellular carcinoma before liver transplantation: a case report.
Polacco M; Vitale A; Valmasoni M; D'Amico F; Gringeri E; Brolese A; Zanus G; Neri D; Carraro A; Pauletto A; Romanelli E; Lo Bello S; Cillo U
Transplant Proc; 2010 May; 42(4):1378-80. PubMed ID: 20534307
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant conversion to sirolimus in liver transplant patients with recurrent hepatocellular carcinoma - preliminary results.
Kornberg A; Küpper B; Tannapfel A; Thrum K; Wilberg J; Bärthel E; Settmacher U
Transpl Int; 2008 Jan; 21(1):96-9. PubMed ID: 17903182
[No Abstract] [Full Text] [Related]
16. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
17. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma.
Schmidinger M; Wenzel C; Locker GJ; Muehlbacher F; Steininger R; Gnant M; Crevenna R; Budinsky AC
Br J Cancer; 2001 Dec; 85(12):1850-2. PubMed ID: 11747325
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin: an anti-cancer immunosuppressant?
Law BK
Crit Rev Oncol Hematol; 2005 Oct; 56(1):47-60. PubMed ID: 16039868
[TBL] [Abstract][Full Text] [Related]
19. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F; Milazzo M; Chieco P; Negrini M; Calin GA; Grazi GL; Pollutri D; Croce CM; Bolondi L; Gramantieri L
Cancer Res; 2010 Jun; 70(12):5184-93. PubMed ID: 20501828
[TBL] [Abstract][Full Text] [Related]
20. Effect of low-dose rapamycin on tumor growth in two human hepatocellular cancer cell lines.
Heuer M; Benkö T; Cicinnati VR; Kaiser GM; Sotiropoulos GC; Baba HA; Treckmann JW; Broelsch CE; Paul A
Transplant Proc; 2009; 41(1):359-65. PubMed ID: 19249557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
